Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2014, Article ID 512508, 6 pages
Research Article

Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin’s Primary Bone Lymphoma

1Hematology Department of the University of Angers, Angers, France
2Hematology Department of the University of Rennes, Rennes, France
3Hematology Department of the University of Tours, Tours, France
4Hematology Department of the University of Brest, Brest, France
5Hematology Department of the University of Bobigny, Bobigny, France
6Hematology Department of the Hospital of Blois, Blois, France
7Hematology Department of the University of Amiens, Amiens, France
8Hematology Department, St. Quentin General Hospital, St. Quentin, France
9University Hospital of Amiens, Department of Clinical Haematology, Avenue Laennec, 80054 Amiens, France

Received 20 October 2013; Revised 20 January 2014; Accepted 27 January 2014; Published 2 March 2014

Academic Editor: Giuseppe G. Saglio

Copyright © 2014 A. Schmidt-Tanguy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventional anthracycline-cyclophosphamide dose and radiotherapy for PBL. Patients and Methods. The GOELAMS prospective multicenter study (1986–1998) enrolled adults with localized high-grade PBL according to age and performance status (PS). Patients <60 years received a high-dose CHOP regimen (VCAP) and those ≥60 years a conventional anthracycline-cyclophosphamide regimen (VCEP-bleomycin); all received intrathecal chemotherapy and local radiotherapy. Results. Among the 26 patients included (VCAP: 19; VCEP-bleomycin: 7), 39% had poor PS ≥2. With a median follow-up of 8 years, overall survival, event-free survival, and relapse-free survival were 64%, 62%, and 65%, respectively, with no significant difference between treatment groups. Poor PS was significantly associated with shorter OS and EFS. Conclusions. Our results confirm the efficacy of our age-based therapeutic strategy. High-doses anthracycline-cyclophosphamide did not improve the outcome. VCEP-bleomycin is effective and well tolerated for old patients. The intensification must be considered for patients with PS ≥2, a poor prognostic factor.